Morgan Stanley’s ProMIS Neurosciences PMN Stock Holding History

Morgan Stanley’s Portfolio PMN Stock Details PMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-72	Closed	-$7.01K	–	7687
2023 Q2	$7.01K	Sell	72 -28	-28%	-$3.72K	﹤0.01%	6914
2023 Q1	$11.9K	Sell	100 -12	-11%	-$1.47K	﹤0.01%	6824
2022 Q4	$12.2K	Sell	112 -125	-53%	-$17.5K	﹤0.01%	6870
2022 Q3	$36K	Buy	+237	New	+$34.9K	﹤0.01%	6555

Other funds holding PMN

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return

CAM

Claret Asset Management Montreal, Quebec, Canada $837M AUM 25.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley's PMN Position: Q3 2023 in Review

Morgan Stanley sold out of ProMIS Neurosciences (PMN) in Q3 2023, closing a stake of 72 shares — an estimated $7.01K sold.

Morgan Stanley first reported a position in PMN in Q3 2022 and held it in 4 quarters. The position peaked at $36K in Q3 2022. 14 funds tracked by Wall St. Rank hold PMN as of Q3 2023.

Morgan Stanley reported no remaining ProMIS Neurosciences position as of Q3 2023 after selling out during the quarter.
Morgan Stanley sold 72 ProMIS Neurosciences shares in Q3 2023, an estimated $7.01K.
Morgan Stanley first reported a position in ProMIS Neurosciences in Q3 2022 and held it in 4 quarters.
Morgan Stanley's ProMIS Neurosciences position peaked at $36K in Q3 2022.
14 funds tracked by Wall St. Rank held ProMIS Neurosciences as of Q3 2023.

Based on Morgan Stanley's 13F filing for Q3 2023, filed 15 Nov 2023.